title: 6-Day continuous infusion of high-dose ifosfamide with bone marrow growth factors in advanced refractory malignancies.
abstract: Ifosfamide is an analogue of cyclophosphamide active in the treatment of numerous tumours. Although its use by continuous infusion seems to be responsible for less toxicity, differences of efficacy and toxicity, observed according to its doses and schedules of administration, still remain debated. The objective of this study was to assess the toxicity of high-dose ifosfamide given by continuous infusion over 6 days and its therapeutic activity in various advanced tumours. Twenty-six patients were treated with 14 g/m2 ifosfamide, an equal dose of MESNA, and routine granulocyte- or granulocyte/macrophage-colony-stimulating factor during the intercycle. Courses were repeated every 3 weeks until disease progression or unacceptable toxicity occurred; 75 cycles were administered. The mean number of cycles per patient was 3 (range 1-11). Extrahaematological toxicity was manageable in most patients, WHO grade II or more neurological (5 patients) and renal (5 patients) toxicities occurring in those heavily pretreated with platinum compounds and presenting peritoneal disease. WHO grade III or more neutropenia occurred in 60% of cycles, while grade III-IV thrombocytopenia and anaemia were observed in 19% of them. Three partial responses (germ-cell tumour, chondrosarcoma, soft-tissue sarcoma) and one complete response (metastatic osteosarcoma) were assessed, all in patients with tumours refractory or resistant to standard-dose ifosfamide, which underlines the possibility of circumventing the resistance to ifosfamide given in conventional schedules. The present results confirm previous reports of changes in the therapeutic index of ifosfamide according to its dose and administration schedule.
authors.affiliation: Service des Maladies Sanguines et Tumorales, Hôpital Paul Brousse, Villejuif, France.
authors.forename: E C
authors.initials: EC
authors.lastname: Brain
authors.forename: A
authors.initials: A
authors.lastname: Mita
authors.forename: P
authors.initials: P
authors.lastname: Soulié
authors.forename: H
authors.initials: H
authors.lastname: Errihani
authors.forename: A C
authors.initials: AC
authors.lastname: Hardy Bessard
authors.forename: M
authors.initials: M
authors.lastname: Chaouche
authors.forename: J
authors.initials: J
authors.lastname: Alexandre
authors.forename: J P
authors.initials: JP
authors.lastname: Delord
authors.forename: E
authors.initials: E
authors.lastname: Cvitkovic
authors.forename: C
authors.initials: C
authors.lastname: Jasmin
authors.forename: J L
authors.initials: JL
authors.lastname: Misset
mesh_terms: D000293:Adolescent; D000328:Adult; D018906:Antineoplastic Agents, Alkylating / Q000008:administration & dosage*; D005260:Female; D016179:Granulocyte Colony-Stimulating Factor / Q000008:administration & dosage; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000008:administration & dosage; D006801:Humans; D007069:Ifosfamide / Q000008:administration & dosage* / Q000009:adverse effects; D007262:Infusions, Intravenous; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000188:drug therapy* / Q000401:mortality
chemical_list: D018906:Antineoplastic Agents, Alkylating; D016179:Granulocyte Colony-Stimulating Factor; D016178:Granulocyte-Macrophage Colony-Stimulating Factor; D007069:Ifosfamide